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Abstract
Background: With regard to the increasing number of antifungal-resistant dermatophytes, the requirement for precise identifica-
tion of causative agents of infections and antifungal susceptibility test is vital. Antifungal susceptibility testing of dermatophytes
plays a pivotal role in managing dermatophytosis. The current study aimed at determining antifungal susceptibility profile of 161
important dermatophyte species isolated from Iranian patients.
Methods: The current descriptive, cross sectional study was conducted on 508 clinically suspected samples of dermatophytosis
collected and identified by conventional methods. All dermatophyte isolates were identified using polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP) method. The susceptibility of dermatophyte strains to two routine antider-
matophyte agents (terbinafine and griseofulvin) was evaluated using micro-dilution method according to CLSI (the clinical and
laboratory standards institute) M38-A2 guidelines. Trichophyton rubrum PTCC 5143 and Candida krusei ATCC 6258 were used as quality
controls.
Results: Among 161 dermatophyte isolates, T. interdigitale was reported as the most frequent species isolated from patients using
PCR-RFLP and Microsporum ferruginum was the least isolated species. The minimum inhibitory concentration (MIC) values of griseo-
fulvin and terbinafine were ranged 0.0312 - 8 and 0.008 - 4µg/mL, respectively. The most susceptible and resistant species to griseo-
fulvin were T. interdigitale (MIC = 0.0312µg/mL) and T. interdigitale/T. rubrum (MIC = 8µg/mL), respectively. The results indicated that
T. verrucosum (MIC = 0.008 µg/mL) was the most susceptible species to terbinafine, whereas T. interdigitale and T. rubrum were the
most resistant species to it (MIC = 4µg/mL).
Conclusions: The obtained results assist clinicians to monitor the trend and be able to choose effective medications to treat patients
with dermatophytosis, especially in countries such as Iran, where dermatophytosis is still a public health problem.
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1. Background
In the last two decades, infections caused by dermato-
phyte species are remarkable public health problems due
to the increasing number of cases, particularly in immuno-
compromised patients (1). Since the traditional methods
are slow and non-specific diagnostic tools to differenti-
ate dermatophyte species and many isolates have atypical
features in primary isolation, a variety of molecular tech-
niques are designed for precise differentiation of dermato-
phyte isolates (2, 3).
Dermatophytosis is generally treated with topical anti-
fungal drugs, with the exception of disseminated or nails
infections. Therapeutic results vary depending on site of
the infection and the causative agent (4). A number of an-
tifungal agents are recommended to treat all types of infec-
tions (5).
Griseofulvin and terbinafine were considered as the
best treatment-of-choice for dermatophytosis (6); 70% -
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100% efficacy is documented for griseofulvin (6-8) and it is
reported that terbinafine provides long-term clinical effi-
cacy and lower relapse (9). However, dermatophyte species
causing onychomycosis do not respond well to treatments
(10), it may be due to drug resistant of causative agents, pe-
ripheral vascular disease, fungal growth patterns, and the
presence of dormant fungal spores (arthrospores) in the
nail (11).
In vitro analysis of the antifungals activity provides the
possibility to compare the efficacy of different drugs; how-
ever, determination of susceptibility pattern helps to de-
velop or select appropriate drug regimens.
There are few studies about activity of antifungal drugs
against dermatophyte species in several regions of Iran
(5, 10, 12-16); hence, the current study aimed at assessing
in vitro activities of griseofulvin and terbinafine against
molecular identified dermatophytes using broth microdi-
lution method.
2. Methods
2.1. Study Design
All patients with dermatophytosis symptoms were en-
rolled in the study, irrespective of their age and gender. All
patients signed a consent form. The patients who received
any antifungal drugs in the past four weeks were excluded
from the study. Patients’ demographic data, such as age
and gender were obtained.
2.2. Isolates
A total of 508 clinically suspected specimens including
skin, nail, and hair were collected from patients referred to
Razi hospital, Tehran, Iran. After culturing the specimens,
all dermatophyte isolates were primarily identified using
conventional methods.
2.3. Molecular Identification
Genomic DNA was extracted using DNG-Plus kit (Sina-
Clon, Iran). Specific identification of species was per-
formed using polymerase chain reaction-restriction frag-
ment length polymorphism (PCR-RFLP) method. After ex-
tracting DNA from the clinical isolates, the ITS1-5.8SrDNA-
ITS4 region was amplified using ITS1 (TCCGTAGGTGAACCT-
GCGG) and ITS4 (TCCTCCGCTTATTGATATGC) primers (3).
In the preliminary screening, all amplicons were di-
gested with the restriction enzyme Mva I (3). To identify iso-
lates with similar RFLP pattern, two additional restriction
enzymes, BsrF I and Mae III were used to differentiate Tri-
chophyton tonsurans/T. equinum and M. canis/M. ferrugineum,
respectively (17). The digested products were analyzed on
2% agarose gel.
2.4. Antifungal Agents
Griseofulvin and terbinafine (Sigma-Aldrich, St. Louis,
MO, USA) powders were dissolved in 100% dimethyl sul-
foxide (Sigma-Aldrich, St. Louis, MO, USA) according
to CLSI (the Clinical and Laboratory Standards Institute)
broth microdilution protocol (18, 19) and diluted in stan-
dard RPMI medium (Roswell Park Memorial Institute 1640)
buffered to pH 7.0 with 0.165 M/L morpholinepropanesul-
fonic acid buffer (MOPS) with L-glutamine without bicar-
bonate (Sigma-Aldrich, St. Louis, MO, USA).
The final concentrations of griseofulvin and
terbinafine in 96-well microplates ranged 64 to 0.125
and 4 to 0.008µg/mL, respectively (19).
2.5. Inoculum Preparation
Inoculum suspensions of fungi were prepared from
10 to 14-day-old cultures grown on potato dextrose agar
(Merck, Germany) at 30°C. Then surface of colonies were
covered with 5 mL of sterile saline (0.85%) and scraped
by tip of a sterile swab and mixture collected in sterile
tubes. The tubes were placed at room temperature for 15
to 20 minutes to remove heavy particles such as hyphae.
Homogeneous conidial suspensions were transferred to
new sterile tubes and turbidity was measured using spec-
trophotometer (Jenway Model 6305) at a wavelength of 530
nm, to optical densities (ODs) 65% transmission. Final in-
oculum concentration (1 - 3× 103 CFU/mL) was obtained by
diluting 1:50 to 1:100 in RPMI 1640 (19).
2.6. Antifungal Susceptibility Testing
A 100-µL of the diluted inoculum suspension was
aliquot to each well. The microplates were incubated at
30°C, and were visually read after seven days of incubation.
The MIC was defined as the point at which the organism
was inhibited 80% for terbinafine and griseofulvin, in com-
parison with positive control (19). T. rubrum PTCC 5143 and
C. krusei ATCC 6258 were used as quality controls.
2.7. Statistical Analysis
MIC range, MIC50, and MIC90 were calculated for all
the isolates using SPSS version 19.
3. Results
Totally, 161 positive cases of dermatophytosis- 88 (54.7%)
male and 73 (45.3%) female- were identified. The age of the
study group ranged 4 to 84 years (mean 43.9). Majority
of the patients were within the age range of 41 - 50 years
(27.3%), followed by 31 - 40 years (16.8%). All primarily iden-
tified dermatophytes were precisely differentiated using
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PCR-RFLP (Table 1). All species of T. verrucosum (n = 5) iden-
tified by the routine laboratory method were reported as
T. interdigitale using molecular method. In the primary
screening by ITS (internal transcribed spacer)-RFLP with
Mva I, T. interdigitale (n = 73), T. rubrum (n = 45), E. flocco-
sum (n = 23), M. gypseum (n = 4), and T. violaceum (n = 2)
were identified (Figure 1). In the secondary RFLP using BsrF
I, four isolates were identified as T. tonsorans. Among 10
strains digested by Mae III, nine isolates were identified as
M. canis and one as M. ferrugineum.
Figure 1. Electrophoretic patterns of PCR-RFLP with mvai for some isolated dermato-
phytes. Lane 1: T. interdigitale, lane 2: M. gypseum, lane 3: E. floccosum, lane 4: T. vio-
laceum, lane 5: T. rubrum, lane M: A 100-bp marker
Table 1. Number of Molecular Identified Species
Dermatophyte Specie Tested Strains, No. (%)
Trichophyton interdigitale 73 (45.3)
Trichophyton rubrum 45 (28)
Epidermophyton floccosum 23 (14.3)
Microsporum canis 9 (5.6)
Microsporum gypseum 4 (2.5)
Trichophyton tonsurans 4 (2.5)
Trichophyton violaceum 2 (1.2)
Microsporum ferruginum 1 (0.6)
Results obtained from the current study showed high
potency of terbinafine against all dermatophyte species. A
significant sensitivity to terbinafine was reported in T. ver-
rucosum (MIC = 0.008 µg/mL), whereas T. interdigitale and
T. rubrum were the most resistant species (MIC = 4 µg/mL)
(Table 2). As shown in Table 2, the most susceptible and
resistant species to griseofulvin were T. interdigitale (MIC
= 0.0312 µg/mL) and T. verrucosum/T. interdigitale (MIC = 8
µg/mL), respectively.
MIC50 and MIC90 for two antidermatophytic agents
were calculated (Table 3).
4. Discussion
Identification of dermatophytes at the species level is
an essential factor to treat patients. Identification of this
closely related group of fungi is classically based on phe-
notypic and physiological characteristics (19). Therefore,
due to the high degree of morphological similarity be-
tween several dermatophyte species, identification mis-
takes are inevitable. Several molecular methods are devel-
oped for precise identification of dermatophyte species,
but it seems that PCR-RFLP analysis is a promising, rapid,
easy, and cost-effective method. In the current study, a vir-
tual and practical PCR-RFLP assay, targeting the ITS-rDNA
region, was used to differentiate common pathogenic der-
matophyte species. The results obtained from the current
study confirmed that molecular assay was more reliable
than conventional method to differentiate several species
(Table 1). It is based on the fact that the traditional meth-
ods were unable to differentiate T. verrucosum and T. menta-
grophytes strains, whereas the molecular method differen-
tiated these strains, precisely.
Similar previous studies from Iran were reported as the
predominant causative agent (16, 17, 20).
The reproducible and reliable antifungal susceptibility
testing are required due to the increasing number of der-
matophytosis, the frequent use of antifungal agents, and
the resulting drug resistance as an important clinical prob-
lem. In vitro susceptibility testing is useful to select more
clinically active agents and plays an essential role to deter-
mine the emerging resistance patterns.
In vitro antifungal susceptibility testing is now devel-
oped for filamentous and yeast fungi, but is not used as
a routine technique to evaluate antifungal activity of sev-
eral components against dermatophytes (21). Several in-
vestigations show considerable variation in susceptibility
of dermatophytes to antifungal drugs that is probably due
to methodological differences among the several research
centers. In the current study, CLSI M38-A2 was used to de-
termine the MIC values of the two antifungal agents.
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Table 2. MIC Values of Two Antifungal Drugs Against Several Species of Dermatophytes
Specie and Drugs
MIC (µg/mL)
0.008 0.0156 0.0312 0.0625 0.125 0.25 0.5 1 2 4 8 16 32 64
Trichophyton interdigitale
GRIS 2 5 22 27 8 4 2 1 2
TRB 1 17 33 11 3 3 1 1 2 1
Trichophyton rubrum
GRIS 3 5 6 19 7 3 2
TRB 10 20 10 1 1 1 1 1
Epidermophyton floccosum
GRIS 8 11 3 1
TRB 2 9 7 4 - - 1
Microsporum canis
GRIS 2 3 3 1
TRB 5 3 1
Microsporum gypseum
GRIS 2 2
TRB 2 1 1
Trichophyton tonsurans
GRIS 2 1 1
TRB 1 2 1
Trichophyton violaceum
GRIS 1 1
TRB 1 - - 1
Microsporum ferruginum
GRIS 1
TRB 1
Abbreviations: GRIS; griseofulvin, TRB; terbinafine.
According to the MIC breakpoints proposed by CLSI,
relatively low levels of terbinafine resistance were ob-
served in dermatophyte strains, proving that this drug en-
compasses suitable activity on a variety of clinical strains.
In the current study, MICs of terbinafine showed a variable
range of activity on the different species of Microsporum
(0.0156 - 0.25 µg/mL), Trichophyton (0.008 - 4 µg/mL) and
Epidermophyton (0.125 - 2µg/mL). The results obtained from
the current study highlighted the use of terbinafine for the
majority of dermatophytosis cases especially in infections
caused by species resistant to griseofulvin. This finding
was in agreement with the results of several previous in-
vestigations (11, 12, 22-25).
In a study by Perea et al. (26), terbinafine indicated less
activity against the tested isolates. The possible reasons for
these differences may be due to time and temperature of
incubation and other technical errors.
In the current study the geometric mean (Gm) MIC of
terbinafine for T. interdigitale, was lower than that of Ansari
et al. (16) and comparable to that of Jo Siu et al. (27). In cases
of T. rubrum and E. floccosum, the Gm MIC of terbinafine
was lower than those of the studies by Esteban et al. (28),
and Adimi et al. (12), respectively. However, the Gm MIC of
terbinafine for T. rubrum and E. floccosum was higher than
those of Ansari et al. (16).
Among nine species of dermatophytes isolated from
nail infections, T. interdigitale and T. rubrum had the lowest
susceptibility to terbinafine. It is a warning that uncon-
trolled use of this drug might result in increasing unre-
sponsiveness in the future.
Despite the good results of griseofulvin against der-
matophyte species, this medicine is not routinely pre-
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Table 3. Comparison of MIC50 and MIC90 Values of Griseofulvin and Terbinafine
Specie and Drug MIC50 (µg/mL) MIC90 (µg/mL) GM Range
Trichophyton interdigitale
GRIS 0.25 0.125 0.257 0.0312 - 4
TRB 0.0312 0.25 0.043 0.008 - 4
Trichophyton rubrum
GRIS 0.5 2 0.455 0.0625 - 4
TRB 0.0312 0.0156 0.043 0.0156 - 4
Epidermophyton floccosum
GRIS 0.125 0.008 0.250 0.125 - 2
TRB 0.0625 0.125 0.053 0.0156 - 1
Microsporum canis
GRIS - - - 0.125 - 1
TRB - - - 0.0312 - 1
Microsporum gypseum
GRIS - - - 0.125 - 0.25
TRB - - - 0.0625 - 0.25
Trichophyton tonsurans
GRIS - - - 0.125 - 0.5
TRB - - - 0.0156 - 0.0625
Trichophyton violaceum
GRIS - - - 0.125 - 0.25
TRB - - - 0.0156 - 0.125
Microsporum ferruginum
GRIS - - - 1
TRB - - - 0.0625
Abbreviations: GM; geometric mean, GRIS; griseofulvin, MIC; minimal inhibitory concentration, TRB; terbinafine.
scribed to treat systemic dermatophytosis (8).
In the current study, the MIC of griseofulvin against
161 isolates ranged 0.0312 to 1 µg/mL. The obtained re-
sults supported the findings of previous studies, which re-
ported good activity of griseofulvin against various der-
matophytes (12, 14, 29). Data indicated that T. interdigitale
was more susceptible to griseofulvin (MIC90, 0.25 µg/mL)
than the other tested species. Griseofulvin showed re-
duced susceptibility to T. rubrum (MIC90, 2 µg/mL). The re-
sults obtained in the current study were in agreement with
those of other studies (10, 12, 26) demonstrating that sus-
ceptibility to griseofulvin varied among the species.
The Gm MIC of griseofulvin reported in the current
study was lower than those of the previous studies (12, 16,
29). Furthermore, 6% of strains showed resistance to grise-
ofulvin. Decreased susceptibility to griseofulvin was re-
ported in the studies by Galuppi et al., (MICs ranging 4 to
8 µg/mL) and Scholz et al. (MICs, 3 µg/mL) (29, 30). In the
literature, resistance to griseofulvin was described for T.
rubrum (26, 31).
4.1. Conclusion
The current study results can assist clinicians to moni-
tor the trend and choose effective medications to treat pa-
tients with dermatophytoses, especially in countries such
as Iran where dermatophytoses is a public health problem.
On the other hand, terbinafine showed excellent in vitro
activity against dermatophyte isolates. It seems to be a
promising therapeutic choice when other therapeutic op-
tions such as griseofulvin are eliminated by the increasing
resistance.
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